

September 2024

Investment Sheet Topadur Pharma AG

Information on the capital increase of CHF 22 million including convertible bonds of CHF 5 million for Q4 2024

About Topadur Pharma AG

Topadur Pharma AG, founded in 2015, is a Swiss clinical-stage biopharmaceutical company developing innovative treatments for aging-related diseases. Our proprietary DualTOP™ technology platform enables the creation of dual-acting drugs that increase cellular cGMP levels to unprecedented levels, stimulating impaired microcirculation more effectively than existing treatments.

Our lead asset, TOP-N53, is currently in Phase 2a clinical development for digital ulcers in systemic sclerosis (SSc), exemplifying our unique approach. By focusing on locally-administered, locally-active therapies, Topadur has shown the potential to achieve superior efficacy and safety profiles compared to systemic treatments, addressing significant unmet medical needs in aging-related diseases.

Investment Strategy

Topadur has a broad portfolio of drug candidates in various development stages, all based on our DualTOP™ technology platform. Our primary strategy is to develop and market TOP-N53 for digital ulcers/SSc, a rare disease that could allow for early market access from EMA. For broader indications like diabetic foot ulcers, we aim to develop TOP-N53 through strategic partnerships with Big Pharma companies. Another key asset is TOP-M119 for alopecia, with secured funding CHF 12 M through our partnership with Oshen Holdings SA for development in Greater China. We seek early partnerships with global pharmaceutical companies for our opportunity assets and indications. Topadur investors can expect a significant return on investment (ROI) from this focused, long-term strategy approved by the Board of Directors, our patented product pipeline, and the upcoming IPO.

Financing Strategy

The funds from the Series C-2 financing round of CHF 22M will be allocated as follows: TOP-N53 for digital ulcers (CHF 6-8 M), TOP-M119 for alopecia (CHF 2M), TOP-N53 for out-licensing agreement for diabetic foot ulcers (CHF 2M) and development of opportunity pipeline with TOP-V122 (CHF 2 M) for Oncology (including radioligand therapy booster), diabetic retinopathy and lung fibrosis. The remaining CHF 8-10M is reserved as a liquidity reserve for 2 years for IPO preparation, general corporate business, and corporate growth. This allocation ensures focused development of our key assets while maintaining flexibility for future opportunities until the planned IPO (2025-2026).

Exit Strategy

Topadur plans an IPO in 2025-2026 with an expected company value of CHF 500M – CHF 1'500M. Key value creation milestones leading to this exit include:

- Successful completion of Phase 2a Proof of Concept study for TOP-N53 in digital ulcers (expected Q3/Q4 2024)

- Securing strategic partnerships for DFU and Alopecia with big pharma companies before IPO.
- Advancement of TOP-M119 for alopecia into clinical development.

Investment Case

- High-value creation through an attractive product pipeline with potential market volumes in the billions of dollars.
- Highly experienced management and board team with longstanding expertise in R&D, management, and commercialization of pharmaceutical products.
- Successful completion of Phase 1 study of TOP-N53 with good tolerability and efficacy profile in healthy volunteers, Phase 2a in patients with digital ulcers in systemic sclerosis, with preliminary data by Q4 2024.
- Orphan drug designation (ODD) for TOP-N53, with fast-track market access and 10-year market exclusivity.

Portfolio Development

- **TOP-N53:** Lead candidate. Wound healing in digital ulcers in SSc patients (orphan drug status) and chronic diabetic foot ulcers as a second indication.
- **TOP-M119:** Medical cosmetics for the treatment of alopecia.
- **TOP-V122:** Diabetic retinopathy, oncology, inflammatory bowel disease, lung fibrosis.

Further Information

Issuer	Topadur Pharma AG
Auditors	KPMG, Zürich
Inception	10 March 2015
Company ID	CHE-481.951.668
Business year	1. January-31. December
Annual report	Annually per 31.3.
Special provisions	Sale of shares as stated in the shareholder agreement until the expected IPO
Price per share	CHF 290 (CHF 270 for a 5M convertible bond)
Current valuation	CHF 78M
Expected IPO	2025-2026
Minimum subscription	CHF 150'000.00
Subscription deadline	30.11.2024
Allocation of shares	Conversion of bond into shares Q4/2024

Product Pipeline

DualTOP™: Topadur has developed the DualTOP™ technology platform, which combines nitric oxide (NO) release with phosphodiesterase-5 (PDE5) inhibition, creating dual-acting drugs that increase cellular cGMP levels to unprecedented levels. This promotes healthy cellular phenotypes, stimulates impaired microcirculation and tissue

regeneration. DualTOP™ drugs are locally administered and locally active, enhancing safety profiles.

TOP-N53: Our lead candidate, selected in 2015, is in clinical development for digital ulcers (DU). The Phase 1 trial successfully met both tolerability and efficacy endpoints. Phase 2a clinical trial completion is expected in Q4 2024. With Orphan Drug Designation (ODD), accelerated access to the USD 1.5 billion (2021) scleroderma market is anticipated. Unlike current systemic treatments, TOP-N53's topical application offers targeted efficacy with minimal side effects. It's also promising for diabetic foot ulcers (DFU), addressing a USD 8.9 billion market with significant unmet needs. Animal models demonstrated unprecedented efficacy and tolerability.

TOP-M119: Developed for alopecia treatment, TOP-M119 has shown over 1000-fold higher efficacy than minoxidil in animal models. This positions it favorably in the USD 2.6 billion market, where current topical treatments have limited efficacy. Topadur has signed a development partnership deal with Oshen Holdings SA to bring this asset to clinical phase 2.

TOP-V122 (Opportunity pipeline): Our most potent dual-acting candidate targets diabetic retinopathy, with ongoing preclinical proof-of-concept results expected Q4-2024. This USD 7.6 billion market lacks effective treatments that don't require frequent injections. Given the unique efficacy of the compound, there is significant potential for additional indications. Additional indications include oncology (colorectal cancer / radioligand therapy booster) and lung fibrosis (USD 2.2 billion market), where TOP-V122's anti-fibrotic effects could be disease-modifying.


Intellectual Properties

Topadur's innovations are protected by a robust patent portfolio, including 3 granted composition of matter patents and 3 formulation patents/applications. Our lead asset, TOP-N53, which currently faces no competitive product, is covered by a composition of matter patent (WO 2017/085056) valid until 2035, with a potential extension to 2040. A formulation patent (WO 2023/052407) could extend protection to 2045. TOP-M119 and TOP-V122 are similarly protected by composition and formulation patents. This strategic IP estate provides strong market exclusivity for our key assets across major markets, enhancing our competitive position and long-term value proposition.

Awards from Topadur Pharma AG

- TOP 100 Swiss Scale-ups 2022, 2023
- TOP 100 Swiss Scale-ups 2020
- TOP 100 Swiss Startups 2019
- Winner ED Dong Sheng Cup 2018
- Winner SEF Award 2018
- TOP 100 Schweizer Startups 2018
- Winner Venture Leaders China 2018
- Winner Swiss Innovation Challenge 2017
- TOP 100 Swiss Startups 2017
- Winner IMD Startup 2016
- CTI-Label-Unternehmen 2016
- TOP 100 Swiss Startups 2016
- Winner Venture Leaders Life Science 2016
- Finalist Swiss Innovation Challenge 2015

Topadur Pharma's Board and Leadership Team



Compensation & Compliance Committee:

Dr. Daniel Vasella
 Dr. Dominik Escher
 Cornelia Gehrig

Audit Committee:

Cornelia Gehrig
 Silvia Scherer
 Prof. Dr. Günther Wess

Contact

Dr Reto Naef
 Chairman | founder

+41 44 755 44 66
reto.naef@topadur.com

Pascal Brenneisen
 Chief Executive Officer |
 Delegate of the Board of Directors

+41 79 344 65 48
pascal.brenneisen@topadur.com

Topadur Pharma AG
 Grabenstrasse 11A
 8952 Schlieren, Switzerland
 +41447554466
info@topadur.com



DISCLAIMER

This document was created by Topadur Pharma AG (hereinafter "Topadur") carefully and to the best of its knowledge and belief. However, Topadur gives no guarantee with regard to its content and completeness and does not accept any liability for losses resulting from the use of this information. The opinions expressed in this document are those of Topadur at the time of writing and are subject to change at any time and without notice. The following risks and uncertainties could influence the accuracy of this document: For example, the future financial position, capital requirements, the progress of research and development, the completion and success of clinical trials for the candidate drugs, current and future cooperation partners, as well as future developments, trends and conditions in the Industry in which Topadur operates. Should one or more of these risks or uncertainties arise or should underlying assumptions prove to be incorrect, the actual results and figures may differ materially from those stated. Unless otherwise noted, all figures are unaudited. The document is for informational purposes only and is for the exclusive use of the recipient. It does not constitute an offer or a recommendation to subscribe or otherwise acquire claims to Topadur and does not release the recipient from making his own assessment. In particular, the recipient is advised to check the information with regard to the compatibility with his own circumstances, if necessary with the help of a consultant. The only thing that is decisive for the subscription of claims is the applicable prospectus as well as the statutes and regulations of Topadur. This document may not be reproduced in whole or in part without the written consent of Topadur. It is expressly aimed only at pension funds and other tax-exempt institutions based in Switzerland that serves occupational pension purposes according to their purpose, as well as at people who manage pension funds and are supervised by FINMA. Every investment involves risks, especially those of fluctuations in value and income. Historical returns and financial market scenarios are no guarantee of current and future results. Regarding performance: There can be no guarantee that the performance of competing companies and/ or the benchmark index will be achieved or exceeded. Topadur is the issuer of securities and/or loans of any kind (including hybrids, etc.). Further information and documents are available on the website www.topadur.com and can be viewed at any time. The current annual report or factsheets can be obtained free of charge from Topadur on request.